长效支气管舒张剂在慢性阻塞性肺疾病稳定期治疗中的应用进展被引量：13

下载PDF

导出

摘要近几年来,慢性阻塞性肺疾病（chronic obstructive pulmonary disease,慢阻肺）因其在世界各国均有较高的发病率和死亡率,所以受到越来越多的关注和重视。慢阻肺的发病机制目前尚不完全明确,它的特征是存在持续的气流受限,并随着疾病的进展,呈进行性加重,部分存在可逆性,同时可存在气道高反应性。

作者王宏俊谭焰

机构地区南京医科大学附属南京医院(南京市第一医院)呼吸内科

出处《临床肺科杂志》 2017年第7期1326-1330,共5页 Journal of Clinical Pulmonary Medicine

关键词慢性阻塞性肺疾病稳定期长效支气管舒张剂 PULMONARY 应用治疗气道高反应性进行性加重发病机制

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献2

1王颖,宋宁,吴建玲.罗氟司特治疗慢性阻塞性肺疾病临床研究现况[J].临床荟萃,2012,27(16):1462-1465. 被引量：10
2骆健峰,朱丹,陈慧,陈卫松,王临英.布地奈德与舒利迭序贯治疗慢性阻塞性肺疾病合并感染的疗效观察[J].中华医院感染学杂志,2013,23(19):4650-4651. 被引量：42

二级参考文献26

1World Health Organization. World health statistics 2008[R]. Geneva,Switzerland:World Health Organization,2008.
2Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities[J]. Proc Am Thorac Soc,2008,5(8) :857-864.
3Giembycz MA,Field SK. R0flumilast:first phosphodiesterase 4 inhibitor approved for treatment of COPD[J]. Drug Des Devel Ther,2010,21 (4) : 147-158.
4Global strategy ~or the diagnosis, management,and prevention of chronic obstructive pulmonary disease revised 2011. [EB/ OL](2012-12) [2012-06-10]. http://www.google. com. hk/ url. htm.
5Hatzelmann A, Morcillo E J, Lungarella G, et al. The preclinical pharmacology of roflumilast-a selective,oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2010,23(4) : 235-256.
6Rabe KF, Baleman ED, O' Donnell D, et al. Roflumilast-an oral antl-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial[J]. Lancet, 2005, 366 (9485) :563-571.
7Calverley PM, Sanchez Toril F, Mclvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2007,176 (2):154-161.
8Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/ M2-112) [EB/OL]. ( 2012-05-04 ) [2012-06-10]. http:// www. clinicaltrials.gov/ct2/show/NCT00430729, htm.
9Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD[J]. Respir Res,2011,27(12):18.
10OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) [EB/OL]. (2012 05-04) E2012-06-103. http://www.clinicaltrials.gov/ct2/show/NCT00076089. htm.